LGND Ligand Pharmaceuticals Incorporated
USHealthcareAs of 2026-07-08 16:00
Why LGND matters now
Ligand Pharmaceuticals Incorporated (LGND) is a US stock in Healthcare. The latest InvestLog snapshot shows $314.88 with -1.42% on the session and $6.31B in market capitalization; recent performance reads 1-month +32.29% and YTD +45.39%.
The latest financial table shown here is Q1 2026, with revenue of $51.7M, net income of $-13.3M, and EPS of $-0.67. Investors can compare that operating picture with valuation signals such as P/E 32.83 and FCF yield 2.2%.
The latest indexable market news headline is "Ligand Pharma: Expect Bright And Exciting Future For This Growing Royalty Aggregator" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $255.00; recent insider activity includes Sabba Stephen L filing M-Exempt; recent congressional disclosure data includes Gilbert Cisneros Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
32.83
PEG
0.01
P/B
5.48
P/S
20.07
EV/EBITDA
26.30
DCF Value
$43.35
FCF Yield
2.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.6%
Operating Margin
36.7%
Net Margin
55.9%
ROE
16.2%
ROA
10.0%
ROIC
5.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $51.7M | $-13.3M | $-0.67 |
| Q4 2025 | $59.7M | $44.8M | $2.12 |
| FY 2025 | $268.1M | $124.5M | $6.13 |
| Q3 2025 | $115.5M | $117.3M | $5.68 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$265.33
Target (Median)
$255.00
Target Range
$252.00 - $289.00
Trading Activity
Insider Trades
Congress Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.04
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.